|Systematic (IUPAC) name|
|Mol. mass||242.622 g/mol|
|(what is this?)|
Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression. Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.
- Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA (February 2000). "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide". Cancer Gene Ther 7 (2): 233–9. doi:10.1038/sj.cgt.7700120. PMID 10770631.
- Newlands ES, Blackledge GR, Slack JA, et al. (February 1992). "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)". Br J Cancer 65 (2): 287–91. doi:10.1038/bjc.1992.57. PMC 1977719. PMID 1739631.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|